The Effect of Pioglitazone on Peroxisome Proliferator-Activated Receptor-γ Target Genes Related to Lipid Storage In Vivo
- 1 July 2004
- journal article
- clinical trial
- Published by American Diabetes Association in Diabetes Care
- Vol. 27 (7) , 1660-1667
- https://doi.org/10.2337/diacare.27.7.1660
Abstract
OBJECTIVE—Pioglitazone is a member of the thiazolidinediones (TZDs), insulin-sensitizing agents used to treat type 2 diabetes. The aim of this study was to define the effect of pioglitazone on the expression of genes related to carbohydrate and lipid metabolism in subcutaneous fat obtained from type 2 diabetic patients. RESEARCH DESIGN AND METHODS—Forty-eight volunteers with type 2 diabetes were divided into two groups treated for 12 weeks with placebo or pioglitazone (30 mg/day). The expression of several genes was quantified by real-time RT-PCR. RESULTS—Pioglitazone treatment increased the expression of genes involved in glycerol-3-phosphate synthesis. The mRNA expression of PEPCK-C and glycerol-3-phosphate dehydrogenase (GPDH) increased (P < 0.01) in patients treated with pioglitazone. There was no difference in glycerol kinase (GyK) mRNA levels. The expression of genes that regulate fatty acid availability in adipocytes, including lipoprotein lipase (LPL) and acetyl-CoA synthetase (ACS), was higher (P < 0.01) in pioglitazone-treated patients. Pioglitazone stimulated (P < 0.0001) expression of c-Cbl-associated protein (CAP), whereas tumor necrosis factor-α, leptin, resistin, angiopoietin like-4, and 11-β-hydroxysteroid dehydrogenase type 1 (11β HSD 1) were not affected by pioglitazone. The baseline peroxisome proliferator-activated receptor (PPAR)-γ1 mRNA was significantly correlated with mRNA for LPL, CAP, ACS, 11β HSD 1, GyK, fatty acid synthase, leptin, and GPDH, whereas PPAR-γ2 mRNA was correlated with CAP, PEPCK-C, leptin, and GPDH. CONCLUSIONS—Treatment with pioglitazone increased body weight, and this is associated with upregulation of some, but not all, genes previously demonstrated as “TZD responsive” in subcutaneous fat. The results suggest that TZDs might increase body weight through the upregulation of genes facilitating adipocyte lipid storage in vivo.Keywords
This publication has 42 references indexed in Scilit:
- Adipose tissue triglyceride turnover, de novo lipogenesis, and cell proliferation in humans measured with2H2OAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Glyceroneogenesis and the Triglyceride/Fatty Acid CycleJournal of Biological Chemistry, 2003
- Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-γBiochemical and Biophysical Research Communications, 2003
- A Novel Heterozygous Mutation in Peroxisome Proliferator-Activated Receptor- Gene in a Patient with Familial Partial LipodystrophyJournal of Clinical Endocrinology & Metabolism, 2002
- Glyceroneogenesis and the Source of Glycerol for Hepatic Triacylglycerol Synthesis in HumansPublished by Elsevier ,2001
- Comprehensive Messenger Ribonucleic Acid Profiling Reveals That Peroxisome Proliferator-Activated Receptor Activation Has Coordinate Effects on Gene Expression in Multiple Insulin-Sensitive TissuesEndocrinology, 2001
- Cloning and Characterization of a Functional Peroxisome Proliferator Activator Receptor-γ-responsive Element in the Promoter of the CAP GeneJournal of Biological Chemistry, 2000
- Troglitazone Effects on Gene Expression in Human Skeletal Muscle of Type II Diabetes Involve Up-Regulation of Peroxisome Proliferator-Activated Receptor-Journal of Clinical Endocrinology & Metabolism, 1998
- PPARγ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytesAtherosclerosis, 1998
- Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids.Journal of Clinical Investigation, 1997